PT-141
PT-141
Couldn't load pickup availability
PT-141, also known as Bremelanotide, is a synthetic peptide that targets melanocortin receptors involved in sexual arousal and libido.
Originally developed as a tanning agent, PT-141 was developed by Palatin Technologies and initially investigated as a potential treatment for erectile dysfunction (ED) and female sexual dysfunction (FSD).
It works as a melanocortin receptor agonist, specifically targeting the melanocortin receptors MC3-R and MC4-R in the central nervous system. By activating these receptors, PT-141 enhances sexual arousal and desire.
Potential Benefits & Mechanism of Action:
- Treatment for Erectile Dysfunction: PT-141 offers an alternative to traditional ED treatments like Viagra by directly targeting the central nervous system and enhancing sexual arousal
- Treatment for Female Sexual Dysfunction: PT-141 has shown promise in treating FSD by increasing libido and sexual satisfaction in women
- Non-Hormonal: Unlike some other sexual dysfunction treatments, PT-141 works independently of hormonal pathways, making it suitable for individuals with hormone-related conditions or those who cannot tolerate hormonal therapies.
Case Studies:
- Animal Studies: Preclinical studies in animals, particularly rodents, have demonstrated PT-141's ability to increase sexual behavior and arousal, supporting its potential efficacy in humans
- Human Trials: Clinical trials have shown positive results in both men and women with sexual dysfunction. In one study, men with ED experienced improvements in erectile function after PT-141 administration, while in another study, women with FSD reported increased sexual desire and satisfaction.
PT-141 activates melanocortin receptors in the brain, enhancing sexual arousal independently of hormone levels.
Clinical trials have shown PT-141 is effective in increasing sexual desire and function in both men and women. It is now commercially available under the brand name Vyleesi.





